Authorised Therapeutic exploratory (Phase II) Small cell lung cancer (SCLC)

Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot receive both treatments at the same time.

EU CTIS ID: 2024-515201-26-00

What this study is testing

Efficacy of Tarlatamab as maintenance treatment assessed by progression free survival. PFS, defined as the time from enrollment to the date of the first documentation of disease progression according to RECIST 1.1 or death from any cause, whichever is earlier

Therapeutic exploratory (Phase II)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

1. Histologically or cytologically documented new diagnosis of LS-SCLC by histology or cytology from brushing, washing, or needle aspiration. Mixed tumors are not eligible.
10. Correct pulmonary function without oxygen supplementation
11. Have voluntarily agreed to participate by giving written consent for the study prior to any specific protocol procedures.
12. Have adequate organ function (hematological and biochemistry parameters) • absolute neutrophil count ³ 1.5 x 109/L • platelet count ³ 100 x 109/L • hemoglobin > 9 g/dL (90 g/L) • Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) or activated partial thromboplastin time (APTT) 1.5 x institutional upper limit of normal (ULN) except for subjects on anticoagulation • Estimated glomerular filtration rate (eGFR) based on Modification of Diet in Renal Disease (MDRD) calculation > 30 mL/min • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)<3 X ULN (or < 5 x ULN for subjects with liver involvement) • Total bilirubin (TBL) < 1.5 X ULN (or < 2 x ULN for subjects with liver involvement) • Pulmonary function: No clinically significant pleural effusion. Pleural effusion managed with indwelling pleural catheter (eg, PleurX) are allowed • Baseline oxygen saturation > 90% on room air • Cardiac ejection fraction ≥ 50%, no clinically significant pericardial effusion as determined by an echocardiogram (ECHO) or multigated acquisition (MUGA) scan, and no clinically significant electrocardiogram (ECG) findings. "
2. Patients who: a. were treated with sequential chemo-radiotherapy b.were treated only with chemotherapy
3. Have at least one lesion that meets criteria for being measurable or non-measurable, as defined by RECIST 1.1.

You likely can't join if

1. Patients expected to require any other form of radiation therapy for LS-SCLC as concurrent radiotherapy (concurrent radiation defined as radiotherapy started during the first or second cycle of chemotherapy)
10. Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association >class II) within 6 months prior to first dose of study treatment
11. Has a known history of Human Immunodeficiency Virus (HIV) infection. Note: HIV testing is not required unless mandated by the local health authority."
12. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus infection (defined as HCV RNA [qualitative] or HCV antibody reactive [HCV Ab], if HCV-RNA is not the local SOC).
13. Has a known history of active tuberculosis.
14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject’s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

See the full eligibility criteria

Who can join

1. Histologically or cytologically documented new diagnosis of LS-SCLC by histology or cytology from brushing, washing, or needle aspiration. Mixed tumors are not eligible.
10. Correct pulmonary function without oxygen supplementation
11. Have voluntarily agreed to participate by giving written consent for the study prior to any specific protocol procedures.
12. Have adequate organ function (hematological and biochemistry parameters) • absolute neutrophil count ³ 1.5 x 109/L • platelet count ³ 100 x 109/L • hemoglobin > 9 g/dL (90 g/L) • Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) or activated partial thromboplastin time (APTT) 1.5 x institutional upper limit of normal (ULN) except for subjects on anticoagulation • Estimated glomerular filtration rate (eGFR) based on Modification of Diet in Renal Disease (MDRD) calculation > 30 mL/min • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)<3 X ULN (or < 5 x ULN for subjects with liver involvement) • Total bilirubin (TBL) < 1.5 X ULN (or < 2 x ULN for subjects with liver involvement) • Pulmonary function: No clinically significant pleural effusion. Pleural effusion managed with indwelling pleural catheter (eg, PleurX) are allowed • Baseline oxygen saturation > 90% on room air • Cardiac ejection fraction ≥ 50%, no clinically significant pericardial effusion as determined by an echocardiogram (ECHO) or multigated acquisition (MUGA) scan, and no clinically significant electrocardiogram (ECG) findings. "
2. Patients who: a. were treated with sequential chemo-radiotherapy b.were treated only with chemotherapy
3. Have at least one lesion that meets criteria for being measurable or non-measurable, as defined by RECIST 1.1.
4. Has completed chemo-radiation or chemotherapy alone without progression of disease per RECIST v1.1
5. Be male or female ≥18 years of age inclusive, on the day of signing informed consent.
6. Have a life expectancy of at least 3 months from the study start.
7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days prior to the first dose of study intervention
8. Toxicities attributed to chemo-radiotherapy treatment have to be resolved to grade ≤1, unless otherwise specified (alopecia is excluded).
9. No clinically significant electrocardiogram (ECG) findings

What rules you out

1. Patients expected to require any other form of radiation therapy for LS-SCLC as concurrent radiotherapy (concurrent radiation defined as radiotherapy started during the first or second cycle of chemotherapy)
10. Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association >class II) within 6 months prior to first dose of study treatment
11. Has a known history of Human Immunodeficiency Virus (HIV) infection. Note: HIV testing is not required unless mandated by the local health authority."
12. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus infection (defined as HCV RNA [qualitative] or HCV antibody reactive [HCV Ab], if HCV-RNA is not the local SOC).
13. Has a known history of active tuberculosis.
14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject’s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
16. Has serious nonhealing wound, ulcer, or bone fracture within 28 days before first dose of study intervention.
17. Female subjects of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of study treatment.
18. Female subjects who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of study treatment.
19. Female subjects planning to become pregnant or donate eggs while on study through 60 days after the last dose of study treatment.
2. Extensive-stage SCLC (ES-SCLC) or any previous diagnosis of transformed non-small cell lung cancer. Mixed tumors (SCLC-NSCLC) are not eligible.
20. Female subjects of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.
21. Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose of study treatment.
22. Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of study treatment.
23. Subject has known sensitivity to any of the products or components to be administered during dosing.
3. Has known history of, or active, neurologic paraneoplastic syndrome of autoimmune nature.
4. Has had major surgery within 4 weeks prior to first dose of study interventions.
5. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
6. Has known history of a second malignancy other than SCLC, unless potentially curative treatment has been completed with no evidence of malignancy for at least 3 years since the initiation of that therapy.
7. Uncontrolled intercurrent active infection at the time of enrollment requiring systemic therapy.
8. Evidence of interstitial lung disease or active, non-infectious pneumonitis
9. History of solid organ transplantation

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.

Explore other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH)Heart failure Coronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.